

DF/HCC's Process for NCI's Clinical Trials Reporting Program

As of January 5, 2009, participation in NCI Clinical Trials Reporting Program (CTRP) is required. To facilitate this process within DF/HCC, the **Quality Assurance Office for Clinical Trials** will be coordinating and registering all trials reviewed by the DFCI IRB which meet the reporting criteria.

For the first quarter of 2009, CTRP is limiting clinical trial registrations to:

- Five participating sites only
 - Dana-Farber/Harvard Cancer Center
 - Mayo Clinic Cancer Center
 - Robert H. Lurie Cancer Center at Northwestern University
 - St. Jude's Children's Research Hospital
 - Wake Forest Comprehensive Cancer Center
- Interventional trials only (all Phases, both drug and device), not observational or ancillary/correlative
- New trials (i.e., trials that received IRB approval to begin enrolling patients January 1, 2009 and later)
- Those trials that are NOT registered with NCI through other means (e.g., CTEP, DCP, CCR). For instance, Cooperative Group trials do not need to be registered.

For more information regarding DF/HCC's process for trial registration, please contact Alyssa K. Dellacroce, QACT Assistant Director, adellacroce@partners.org or (617) 632-3731.

Please see <http://ctrp.nci.nih.gov> for more NCI information on CTRP.